I
Idriss Bennacef
Researcher at Merck & Co.
Publications - 34
Citations - 2105
Idriss Bennacef is an academic researcher from Merck & Co.. The author has contributed to research in topics: Translocator protein & Radiosynthesis. The author has an hindex of 16, co-authored 33 publications receiving 1737 citations. Previous affiliations of Idriss Bennacef include University of Caen Lower Normandy & Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28
David R. Owen,Astrid Yeo,Roger N. Gunn,Roger N. Gunn,Roger N. Gunn,Kijoung Song,Graham Wadsworth,Andrew J.M. Lewis,Christopher J. Rhodes,David J Pulford,Idriss Bennacef,Christine A. Parker,Christine A. Parker,Pamela Stjean,Lon R. Cardon,Vincent Mooser,Paul M. Matthews,Paul M. Matthews,Eugenii A. Rabiner,Eugenii A. Rabiner,Justin P. Rubio +20 more
TL;DR: Testing for an underlying genetic mechanism to explain the TSPO Ala147Thr polymorphism, which predicts PBR28 binding affinity in human platelets, and testing for this polymorphism may allow quantitative interpretation of T SPO PET studies with these radioligands.
Journal ArticleDOI
Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands
David R. Owen,Roger N. Gunn,Eugenii A. Rabiner,Idriss Bennacef,Masahiro Fujita,William C. Kreisl,Robert B. Innis,Victor W. Pike,Richard Reynolds,Paul M. Matthews,Christine A. Parker +10 more
TL;DR: All TSPO PET ligands in current clinical application recognize HABs, LABs and MABs in brain tissue in vitro, and three binding affinity patterns were found in brains from subjects without neurologic disease in similar proportions to those reported from studies of MS brains.
Journal ArticleDOI
Two Binding Sites for [3H]PBR28 in Human Brain: Implications for TSPO PET Imaging of Neuroinflammation
David R. Owen,Owain W. Howell,Sac-Pham Tang,Lisa Wells,Idriss Bennacef,Mats Bergström,Roger N. Gunn,Roger N. Gunn,Eugenii A. Rabiner,Eugenii A. Rabiner,Martin R. Wilkins,Richard Reynolds,Paul M. Matthews,Paul M. Matthews,Christine A. Parker +14 more
TL;DR: The existence of three different binding patterns with PBR28 suggests that a reduction in [11C]PBR28 binding may not be interpreted simply as a Reduction in TSPO density, and the functional significance of differences in binding characteristics warrants further investigation.
Journal ArticleDOI
Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles.
Eric D. Hostetler,Abbas Walji,Zhizhen Zeng,Patricia Miller,Idriss Bennacef,Cristian Salinas,Brett Connolly,Liza Gantert,Hyking Haley,Marie A. Holahan,Mona Purcell,Kerry Riffel,Talakad G. Lohith,Paul J. Coleman,Aileen Soriano,Aimie Ogawa,Serena Xu,Xiaoping Zhang,Elizabeth Joshi,Joseph Della Rocca,David Hesk,David J. Schenk,Jeffrey L. Evelhoch +22 more
TL;DR: 18F-MK-6240 is a promising PET tracer for the in vivo quantification of NFTs in AD patients, indicating favorable tracer kinetics and distribution in the brain.
Journal ArticleDOI
Discovery of 6-(Fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)
Abbas Walji,Eric D. Hostetler,Harold G. Selnick,Zhizhen Zeng,Patricia Miller,Idriss Bennacef,Cristian Salinas,Brett Connolly,Liza Gantert,Marie A. Holahan,Stacey O'Malley,Mona Purcell,Kerry Riffel,Jing Li,Jaume Balsells,Julie A. O'Brien,Stacey Melquist,Aileen Soriano,Xiaoping Zhang,Aimie Ogawa,Serena Xu,Elizabeth Joshi,Joseph Della Rocca,Fred Hess,Joel B. Schachter,David Hesk,David J. Schenk,Arie Struyk,Kerim Babaoglu,Talakad G. Lohith,Yaode Wang,Kun Yang,Jianmin Fu,Jeffrey L. Evelhoch,Paul J. Coleman +34 more
TL;DR: 6 exhibits high specificity and selectivity for binding to NFTs, with suitable physicochemical properties and in vivo pharmacokinetics.